1. Preconditioning (in which a stimulus below the threshold of damage is applied, leading to tissue resistance to the same, or different stimuli given beyond damage threshold) is an attractive experimental strategy to identify endogenous protective mechanisms that could be therapeutically implemented. The lipid mediator sphingosine 1-phosphate (S1P) plays a role in preconditioning, protecting the heart and kidney against ischemia/reperfusion injury. Sphingosine kinase 2 (SK2) is the major S1P-synthezising enzyme in brain and is up-regulated in neurons in response to ischemia. SK2 is a BH3-only protein, that can interact with the cell death-related protein Bcl-xL, suggesting that this enzyme isoform has S1P-independent actions. Together with colleagues at Soochow University, we have shown that TAT-SPK2 peptide protects against cerebral ischemia/reperfusion neuronal injury both in vivo and in vitro. TAT-SPK2 directly binds to Bcl-2 and disrupts the Beclin-1/Bcl-2 complex and BNIP3/Bcl-2 complex to induce mitophagy. TAT-SPK2 peptide may become a potential candidate for the treatment of ischemic stroke.
2. Neuroprotection The only specific drug available for the management of stroke, recombinant tissue plasminogen activator (tPA), can only be used in a small minority of patients. Thus, the need for an effective and easily administered treatment remains paramount. We have shown that the sphingosine 1-phosphate modulator fingolimod is effective in various animal models of ischemic stroke. Based on these findings, we received Health Research Board funding for preclinical study aimed at establishing the potential of fingolimod as an acute stroke therapeutic agent. Specifically, our goal was to determine the optimal fingolimod administration protocol by examining dose-response, optimal duration of treatment and dosing paradigm.S Our second gola was to confirm the efficacy of fingolimod under clinically relevant circumstances (aged animals and animals with common co-morbid states - hypertension, type II diabetes and hyperlipidemia). Surprisingly, these studies failed to show a consistent effect of fingolimod. Our group is currently examining possible causes for the different outcome in these and previous studies. Using flow cytometry studies, we are also characterizing the profile of various immune cells populations in animals models (following treatment with various immunomodulators) or in stroke patients. We hypothesize that a better understanding of the role of the adaptive immune system in stroke, in particular that of regulatory T cells (Tregs), will lead to interventions that will improve patient outcome.
Biochemical pharmacology of G protein-coupled receptors
Vascular physiology
Central Nervous System Pharmacology and Therapeutics
Biography
Christian Waeber joined University College Cork (UCC) in 2013; he is Professor of Pharmacology, a joint appointment between the School of Pharmacy and the Department of Pharmacology. He is currently Head of the Department of Pharmacology and Therapeutics.
Early in his career, Christian worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. Christian then joined as a post-doctoral fellow the laboratory of Joel Bockaert, at the “Centre CNRS-INSERM de Pharmacologie-Endocrinologie” in Montpellier. In 1993, he joined Harvard Medical School to characterize the pharmacological profile of 5-HT1-like receptors inhibiting neurogenic inflammation, a research carried out in collaboration with Michael Moskowitz. Their work led to the suggestion that specific 5-HT1F receptor agonists would be effective acute antimigraine agents devoid of cardiovascular side-effects. The recent approval of Lasmiditan proved this notion to be correct.
Over the last 20 years, Christian has moved away from 5-HT to focus on the role of sphingosine-1-phosphate (S1P) receptors in various pathophysiological processes. His studies on blood vessels are significant for the treatment of cerebrovascular disorders (e.g. stroke, vasospasm), and conditions such as diabetes, atherosclerosis, pulmonary hypertension or cancer. Christian’s team has also shown that S1P receptors have a widespread distribution both in adult and developing brain. They have characterized the CNS distribution of the S1P synthesizing enzyme, sphingosine kinase (SK), showing that it is up-regulated in neurons following ischemia. Finally, they have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P (preconditioning) protects the brain from ischemia-induced damage. Finally, Christian’s team has shown that administering fingolimod as late as 24 hours after reperfusion in a mouse model promotes long-term stroke recovery, and that fingolimod reduces the neurological deficit and infarct volume after in situ thrombo-embolic occlusion of the middle cerebral artery, a model likely to better mimic the features of stroke in humans; combination of fingolimod and tPA improved the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated to delayed administration to tPA. Because fingolimod’s mechanism of action is thought to involve lymphocytes, Christian’s team is now characterizing the effect of immune-modulating agents such as fingolimod on lymphocyte trafficking, with special emphasis on their effects on regulatory T cells (Tregs).
Christian is also involved in clinical studies aimed at characterizing the profiles of various circulating immune cell populations in the hours and days following an acute ischemic stroke. This will lead to a better understanding of the role of the immune system in stroke recovery.
Early in his career, Christian worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. Christian then joined as a post-doctoral fellow the laboratory of Joel Bockaert, at the “Centre CNRS-INSERM de Pharmacologie-Endocrinologie” in Montpellier. In 1993, he joined Harvard Medical School to characterize the pharmacological profile of 5-HT1-like receptors inhibiting neurogenic inflammation, a research carried out in collaboration with Michael Moskowitz. Their work led to the suggestion that specific 5-HT1F receptor agonists would be effective acute antimigraine agents devoid of cardiovascular side-effects. The recent approval of Lasmiditan proved this notion to be correct.
Over the last 20 years, Christian has moved away from 5-HT to focus on the role of sphingosine-1-phosphate (S1P) receptors in various pathophysiological processes. His studies on blood vessels are significant for the treatment of cerebrovascular disorders (e.g. stroke, vasospasm), and conditions such as diabetes, atherosclerosis, pulmonary hypertension or cancer. Christian’s team has also shown that S1P receptors have a widespread distribution both in adult and developing brain. They have characterized the CNS distribution of the S1P synthesizing enzyme, sphingosine kinase (SK), showing that it is up-regulated in neurons following ischemia. Finally, they have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P (preconditioning) protects the brain from ischemia-induced damage. Finally, Christian’s team has shown that administering fingolimod as late as 24 hours after reperfusion in a mouse model promotes long-term stroke recovery, and that fingolimod reduces the neurological deficit and infarct volume after in situ thrombo-embolic occlusion of the middle cerebral artery, a model likely to better mimic the features of stroke in humans; combination of fingolimod and tPA improved the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated to delayed administration to tPA. Because fingolimod’s mechanism of action is thought to involve lymphocytes, Christian’s team is now characterizing the effect of immune-modulating agents such as fingolimod on lymphocyte trafficking, with special emphasis on their effects on regulatory T cells (Tregs).
Christian is also involved in clinical studies aimed at characterizing the profiles of various circulating immune cell populations in the hours and days following an acute ischemic stroke. This will lead to a better understanding of the role of the immune system in stroke recovery.
Christian Waeber joined University College Cork (UCC) in 2013; he is Professor of Pharmacology, a joint appointment between the School of Pharmacy and the Department of Pharmacology. He is currently Head of the Department of Pharmacology and Therapeutics.
Early in his career, Christian worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. Christian then joined as a post-doctoral fellow the laboratory of Joel Bockaert, at the “Centre CNRS-INSERM de Pharmacologie-Endocrinologie” in Montpellier. In 1993, he joined Harvard Medical School to characterize the pharmacological profile of 5-HT1-like receptors inhibiting neurogenic inflammation, a research carried out in collaboration with Michael Moskowitz. Their work led to the suggestion that specific 5-HT1F receptor agonists would be effective acute antimigraine agents devoid of cardiovascular side-effects. The recent approval of Lasmiditan proved this notion to be correct.
Over the last 20 years, Christian has moved away from 5-HT to focus on the role of sphingosine-1-phosphate (S1P) receptors in various pathophysiological processes. His studies on blood vessels are significant for the treatment of cerebrovascular disorders (e.g. stroke, vasospasm), and conditions such as diabetes, atherosclerosis, pulmonary hypertension or cancer. Christian’s team has also shown that S1P receptors have a widespread distribution both in adult and developing brain. They have characterized the CNS distribution of the S1P synthesizing enzyme, sphingosine kinase (SK), showing that it is up-regulated in neurons following ischemia. Finally, they have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P (preconditioning) protects the brain from ischemia-induced damage. Finally, Christian’s team has shown that administering fingolimod as late as 24 hours after reperfusion in a mouse model promotes long-term stroke recovery, and that fingolimod reduces the neurological deficit and infarct volume after in situ thrombo-embolic occlusion of the middle cerebral artery, a model likely to better mimic the features of stroke in humans; combination of fingolimod and tPA improved the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated to delayed administration to tPA. Because fingolimod’s mechanism of action is thought to involve lymphocytes, Christian’s team is now characterizing the effect of immune-modulating agents such as fingolimod on lymphocyte trafficking, with special emphasis on their effects on regulatory T cells (Tregs).
Christian is also involved in clinical studies aimed at characterizing the profiles of various circulating immune cell populations in the hours and days following an acute ischemic stroke. This will lead to a better understanding of the role of the immune system in stroke recovery.
Early in his career, Christian worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. Christian then joined as a post-doctoral fellow the laboratory of Joel Bockaert, at the “Centre CNRS-INSERM de Pharmacologie-Endocrinologie” in Montpellier. In 1993, he joined Harvard Medical School to characterize the pharmacological profile of 5-HT1-like receptors inhibiting neurogenic inflammation, a research carried out in collaboration with Michael Moskowitz. Their work led to the suggestion that specific 5-HT1F receptor agonists would be effective acute antimigraine agents devoid of cardiovascular side-effects. The recent approval of Lasmiditan proved this notion to be correct.
Over the last 20 years, Christian has moved away from 5-HT to focus on the role of sphingosine-1-phosphate (S1P) receptors in various pathophysiological processes. His studies on blood vessels are significant for the treatment of cerebrovascular disorders (e.g. stroke, vasospasm), and conditions such as diabetes, atherosclerosis, pulmonary hypertension or cancer. Christian’s team has also shown that S1P receptors have a widespread distribution both in adult and developing brain. They have characterized the CNS distribution of the S1P synthesizing enzyme, sphingosine kinase (SK), showing that it is up-regulated in neurons following ischemia. Finally, they have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P (preconditioning) protects the brain from ischemia-induced damage. Finally, Christian’s team has shown that administering fingolimod as late as 24 hours after reperfusion in a mouse model promotes long-term stroke recovery, and that fingolimod reduces the neurological deficit and infarct volume after in situ thrombo-embolic occlusion of the middle cerebral artery, a model likely to better mimic the features of stroke in humans; combination of fingolimod and tPA improved the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated to delayed administration to tPA. Because fingolimod’s mechanism of action is thought to involve lymphocytes, Christian’s team is now characterizing the effect of immune-modulating agents such as fingolimod on lymphocyte trafficking, with special emphasis on their effects on regulatory T cells (Tregs).
Christian is also involved in clinical studies aimed at characterizing the profiles of various circulating immune cell populations in the hours and days following an acute ischemic stroke. This will lead to a better understanding of the role of the immune system in stroke recovery.
Research Interests
My research is centered on the role of sphingosine-1-phosphate (S1P) receptor stimulation in various pathological conditions. My team has shown that S1P receptors have a widespread distribution both in the adult and in the developing brain, in which S1P might play a key role, based on our finding that it induces proliferation and morphological changes of neural progenitor cells. We have also characterized the distribution of the S1P synthesizing enzyme, sphingosine kinase (SPK), in brain, shown that it is up-regulated in neurons following ischemia. Finally, we have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P protects the brain from ischemia-induced damage. My current studies center on preconditioning and neuroprotection in the context of ischemic stroke and intracerebral haemorrhage, and aim at better understanding the role of the adaptive immune system in stroke outcome.1. Preconditioning (in which a stimulus below the threshold of damage is applied, leading to tissue resistance to the same, or different stimuli given beyond damage threshold) is an attractive experimental strategy to identify endogenous protective mechanisms that could be therapeutically implemented. The lipid mediator sphingosine 1-phosphate (S1P) plays a role in preconditioning, protecting the heart and kidney against ischemia/reperfusion injury. Sphingosine kinase 2 (SK2) is the major S1P-synthezising enzyme in brain and is up-regulated in neurons in response to ischemia. SK2 is a BH3-only protein, that can interact with the cell death-related protein Bcl-xL, suggesting that this enzyme isoform has S1P-independent actions. Together with colleagues at Soochow University, we have shown that TAT-SPK2 peptide protects against cerebral ischemia/reperfusion neuronal injury both in vivo and in vitro. TAT-SPK2 directly binds to Bcl-2 and disrupts the Beclin-1/Bcl-2 complex and BNIP3/Bcl-2 complex to induce mitophagy. TAT-SPK2 peptide may become a potential candidate for the treatment of ischemic stroke.
2. Neuroprotection The only specific drug available for the management of stroke, recombinant tissue plasminogen activator (tPA), can only be used in a small minority of patients. Thus, the need for an effective and easily administered treatment remains paramount. We have shown that the sphingosine 1-phosphate modulator fingolimod is effective in various animal models of ischemic stroke. Based on these findings, we received Health Research Board funding for preclinical study aimed at establishing the potential of fingolimod as an acute stroke therapeutic agent. Specifically, our goal was to determine the optimal fingolimod administration protocol by examining dose-response, optimal duration of treatment and dosing paradigm.S Our second gola was to confirm the efficacy of fingolimod under clinically relevant circumstances (aged animals and animals with common co-morbid states - hypertension, type II diabetes and hyperlipidemia). Surprisingly, these studies failed to show a consistent effect of fingolimod. Our group is currently examining possible causes for the different outcome in these and previous studies. Using flow cytometry studies, we are also characterizing the profile of various immune cells populations in animals models (following treatment with various immunomodulators) or in stroke patients. We hypothesize that a better understanding of the role of the adaptive immune system in stroke, in particular that of regulatory T cells (Tregs), will lead to interventions that will improve patient outcome.
Publications
Peer Reviewed Journals
| Year | Publication | |
|---|---|---|
| (2024) | 'Extended siponimod release via low-porosity PLGA fibres: a comprehensive three-month in vitro evaluation for neovascular ocular diseases' Alshaikh RA;Chullipalliyalil K;Waeber C;Ryan KB; (2024) 'Extended siponimod release via low-porosity PLGA fibres: a comprehensive three-month in vitro evaluation for neovascular ocular diseases'. Biomaterials Science, [DOI] [Details] | |
| (2024) | 'In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits' Alshaikh RA;Salah El Din RA;Zaki RGE;Waeber C;Ryan KB; (2024) 'In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits'. Molecular Pharmaceutics, 21 (7) [DOI] [Details] | |
| (2023) | 'The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside' Mitsikostas DD;Waeber C;Sanchez-Del-Rio M;Raffaelli B;Ashina H;Maassen van den Brink A;Andreou A;Pozo-Rosich P;Rapoport A;Ashina M;Moskowitz MA; (2023) 'The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside'. Nature Reviews. Neurology, [DOI] [Details] | |
| (2023) | 'Siponimod as a novel inhibitor of retinal angiogenesis: in vitro and in vivo evidence of therapeutic efficacy' Alshaikh RA;Zaki RGE;Salah El Din RA;Ryan KB;Waeber C; (2023) 'Siponimod as a novel inhibitor of retinal angiogenesis: in vitro and in vivo evidence of therapeutic efficacy'. Journal of Pharmacology and Experimental Therapeutics, [DOI] [Details] | |
| (2023) | 'The impact of fingolimod on Treg function in brain ischaemia' Malone K;Shearer JA;Waeber C;Moore AC; (2023) 'The impact of fingolimod on Treg function in brain ischaemia'. European Journal of Immunology, [DOI] [Details] | |
| (2023) | 'Estrogen modulation of cortical spreading depression' Kudo C;Harriott AM;Moskowitz MA;Waeber C;Ayata C; (2023) 'Estrogen modulation of cortical spreading depression'. The Journal Of Headache And Pain, 24 (1) [DOI] [Details] | |
| (2022) | 'Recombinant pregnancy-specific glycoprotein-1-Fc reduces functional deficit in a mouse model of permanent brain ischaemia' Malone K;Shearer JA;Williams JM;Moore AC;Moore T;Waeber C; (2022) 'Recombinant pregnancy-specific glycoprotein-1-Fc reduces functional deficit in a mouse model of permanent brain ischaemia'. Brain, Behavior, & Immunity - Health, 25 [DOI] [Details] | |
| (2022) | 'Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities' Diaz, ACDC;Malone, K;Shearer, JA;Moore, AC;Waeber, C (2022) 'Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities'. Frontiers in pharmacology, 13 [DOI] [Details] | |
| (2022) | 'Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies' Alshaikh RA;Waeber C;Ryan KB; (2022) 'Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies'. Advanced Drug Delivery Reviews, 187 [DOI] [Details] | |
| (2021) | 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod' Diaz Diaz AC;Malone K;Shearer JA;Moore AC;Waeber C; (2021) 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod'. Data In Brief, 36 [DOI] [Details] | |
| (2021) | 'The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia' Malone K;Diaz Diaz AC;Shearer JA;Moore AC;Waeber C; (2021) 'The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia'. Journal of neuroinflammation, 18 (1) [DOI] [Details] | |
| (2021) | 'Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage' Diaz, ADC;Shearer, JA;Malone, K;Waeber, C (2021) 'Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage'. Frontiers in pharmacology, 11 [DOI] [Details] | |
| (2021) | 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE(-/-) mice in the presence and absence of immunomodulation with fingolimod' Diaz, ACD;Malone, K;Shearer, JA;Moore, AC;Waeber, C (2021) 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE(-/-) mice in the presence and absence of immunomodulation with fingolimod'. Data In Brief, 36 [DOI] [Details] | |
| (2021) | 'Sphingosine 1-phosphate, a potential target in neovascular retinal disease' Alshaikh, Rasha A.; Ryan, Katie B.; Waeber, Christian (2021) 'Sphingosine 1-phosphate, a potential target in neovascular retinal disease'. British Journal of Ophthalmology, [DOI] [Full Text] [Details] | |
| (2020) | 'Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells' Sartawi, Zaid;Ryan, Katie B.;Waeber, Christian (2020) 'Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells'. European Journal of Pharmacology, 882 :1-11 [DOI] [Full Text] [Details] | |
| (2020) | 'A sphingosine kinase 2-mimicking TAT-peptide protects neurons against ischemia-reperfusion injury by activating BNIP3-mediated mitophagy' Chen, Jia-Li; Wang, Xin-Xin; Chen, Lei; Tang, Jie; Xia, Yun-Fei; Qian, Ke; Qin, Zheng-Hong; Waeber, Christian; Sheng, Rui (2020) 'A sphingosine kinase 2-mimicking TAT-peptide protects neurons against ischemia-reperfusion injury by activating BNIP3-mediated mitophagy'. Neuropharmacology, 181 [DOI] [Full Text] [Details] | |
| (2020) | 'Development of electrospun polymer scaffolds for the localized and controlled delivery of siponimod for the management of critical bone defects' Sartawi, Z;Waeber, C;Schipani, E;Ryan, KB (2020) 'Development of electrospun polymer scaffolds for the localized and controlled delivery of siponimod for the management of critical bone defects'. International Journal of Pharmaceutics, 590 [DOI] [Details] | |
| (2019) | 'The immune system and stroke: from current targets to future therapy' Malone, K;Amu, S;Moore, AC;Waeber, C (2019) 'The immune system and stroke: from current targets to future therapy'. Immunology And Cell Biology, 97 :5-16 [DOI] [Details] | |
| (2019) | 'Immunomodulatory Therapeutic Strategies in Stroke' Malone K;Amu S;Moore AC;Waeber C; (2019) 'Immunomodulatory Therapeutic Strategies in Stroke'. Frontiers In Pharmacology, 10 [DOI] [Details] | |
| (2019) | 'Immunomodulatory Therapeutic Strategies in Stroke' Malone, K;Amu, S;Moore, AC;Waeber, C (2019) 'Immunomodulatory Therapeutic Strategies in Stroke'. Frontiers In Pharmacology, 10 [DOI] [Details] | |
| (2018) | 'The immune system and stroke: from current targets to future therapy' Malone, Kyle; Amu, Sylvie; Moore, Anne C.; Waeber, Christian (2018) 'The immune system and stroke: from current targets to future therapy'. Immunology And Cell Biology, [DOI] [Full Text] [Details] | |
| (2017) | 'Sphingosine kinase 2 activates autophagy and protects neurons against ischemic injury through interaction with Bcl-2 via its putative BH3 domain' Song, DD;Zhang, TT;Chen, JL;Xia, YF;Qin, ZH;Waeber, C;Sheng, R (2017) 'Sphingosine kinase 2 activates autophagy and protects neurons against ischemic injury through interaction with Bcl-2 via its putative BH3 domain'. Cell Death &Amp; Disease, 8 [DOI] [Details] | |
| (2016) | 'CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation' Hayakawa, K,Pham, LDD,Seo, JH,Miyamoto, N,Maki, T,Terasaki, Y,Sakadzic, S,Boas, D,van Leyen, K,Waeber, C,Kim, KW,Arai, K,Lo, EH (2016) 'CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation'. Journal Of Cerebral Blood Flow And Metabolism, 36 :781-793 [DOI] [Details] | |
| (2016) | 'Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis' Orset, C,Haelewyn, B,Allan, SM,Ansar, S,Campos, F,Cho, TH,Durand, A,El Amki, M,Fatar, M,Garcia-Yebenes, I,Gauberti, M,Grudzenski, S,Lizasoain, I,Lo, E,Macrez, R,Margaill, I,Maysami, S,Meairs, S,Nighoghossian, N,Orbe, J,Paramo, JA,Parienti, JJ,Rothwell, NJ,Rubio, M,Waeber, C,Young, AR,Touze, E,Vivien, D (2016) 'Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis'. Stroke; a journal of cerebral circulation, 47 :1312-1318 [DOI] [Details] | |
| (2016) | 'Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)' Klionsky, DJ, ... Waeber, C, et al (2016) 'Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)'. Autophagy, 12 (1):1-222 [DOI] [Details] | |
| (2015) | 'CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation' Hayakawa K, Pham LD, Seo JH, Miyamoto N, Maki T, Terasaki Y, Sakadžić S, Boas D, van Leyen K, Waeber C, Kim KW, Arai K, Lo EH (2015) 'CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation'. Journal Of Cerebral Blood Flow And Metabolism, Epub ahead of print [DOI] [Details] | |
| (2014) | 'Preconditioning Stimuli Induce Autophagy via Sphingosine Kinase 2 in Mouse Cortical Neurons' Sheng, R,Zhang, TT,Felice, VD,Qin, T,Qin, ZH,Smith, CD,Sapp, E,Difiglia, M,Waeber, C (2014) 'Preconditioning Stimuli Induce Autophagy via Sphingosine Kinase 2 in Mouse Cortical Neurons'. The Journal of Biological Chemistry, 289 :20845-20857 [DOI] [Details] | |
| (2014) | 'Recognition Memory Impairments After Subcortical White Matter Stroke in Mice' Blasi, F;Wei, Y;Balkaya, M;Tikka, S;Mandeville, JB;Waeber, C;Ayata, C;Moskowitz, MA (2014) 'Recognition Memory Impairments After Subcortical White Matter Stroke in Mice'. Stroke, 45 :1468-1473 [DOI] [Details] | |
| (2014) | 'Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage' Lu, L;Barfejani, AH;Qin, T;Dong, Q;Ayata, C;Waeber, C (2014) 'Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage'. Brain Research, 1555 :89-96 [DOI] [Details] | |
| (2014) | 'Preconditioning stimuli induce autophagy via sphingosine kinase 2 in mouse cortical neurons' Sheng, R; Zhang, TT; Felice, VD; Qin, T; Qin, ZH; Smith, CD; Sapp, E; Difiglia, M; Waeber, C (2014) 'Preconditioning stimuli induce autophagy via sphingosine kinase 2 in mouse cortical neurons'. Journal of Biological Chemistry, [Details] | |
| (2014) | 'Sphingosine-1-Phosphate as a Potential Target for the Treatment of Myocardial Infarction' Waeber C, Walther T. (2014) 'Sphingosine-1-Phosphate as a Potential Target for the Treatment of Myocardial Infarction'. Circulation Journal, (78):795-802 [Details] | |
| (2014) | 'Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage' Lu L, Barfejani AH, Qin T, Dong Q, Ayata C, Waeber C (2014) 'Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage'. Brain Research, 1555 :89-96 [DOI] [Details] | |
| (2014) | 'Recognition Memory Impairments After Subcortical White Matter Stroke in Mice' Blasi F, Wei Y, Balkaya M, Tikka S, Mandeville JB, Waeber C, Ayata C, Moskowitz MA. (2014) 'Recognition Memory Impairments After Subcortical White Matter Stroke in Mice'. Stroke, [DOI] [Details] | |
| (2013) | 'Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model' Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, Waeber C (2013) 'Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model'. Stroke; a journal of cerebral circulation, 44 (2):505-511 [DOI] [Details] | |
| (2013) | 'Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice' Wang QM, Wei Y, Zheng Y, Waeber C (2013) 'Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice'. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists, 92 (2):143-150 [DOI] [Details] | |
| (2013) | 'Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model' Campos, F,Qin, T,Castillo, J,Seo, JH,Arai, K,Lo, EH,Waeber, C (2013) 'Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model'. Stroke; a journal of cerebral circulation, 44 [DOI] [Details] | |
| (2013) | 'Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice' Fukaya M, Tamura Y, Chiba Y, Tanioka T, Mao J, Inoue Y, Yamada M, Waeber C, Ido-Kitamura Y, Kitamura T, Kaneki M. (2013) 'Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice'. Biochem Biophys Res Commun, 442 (1-2):92-98 [DOI] [Details] | |
| (2012) | 'Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations' Eikermann-Haerter K, Lee JH, Yuzawa I, Liu CH, Zhou Z, Shin HK, Zheng Y, Qin T, Kurth T, Waeber C, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2012) 'Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations'. Circulation, 125 (2):335-345 [DOI] [Details] | |
| (2012) | 'Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinases' Simão F, Pagnussat AS, Seo JH, Navaratna D, Leung W, Lok J, Guo S, Waeber C, Salbego CG, Lo EH (2012) 'Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinases'. Journal of Cerebral Blood Flow and Medabolism, 32 (5):884-895 [DOI] [Details] | |
| (2012) | 'Sphingosine kinase 2 mediates cerebral preconditioning and protects the mouse brain against ischemic injury' Yung LM, Wei Y, Qin T, Wang Y, Smith CD, Waeber C (2012) 'Sphingosine kinase 2 mediates cerebral preconditioning and protects the mouse brain against ischemic injury'. Stroke; a journal of cerebral circulation, 43 (1):199-204 [DOI] [Details] | |
| (2012) | 'Multicolored stain-free histopathology with coherent Raman imaging' Freudiger CW, Pfannl R, Orringer DA, Saar BG, Ji M, Zeng Q, Ottoboni L, Ying W, Waeber C, Sims JR, De Jager PL, Sagher O, Philbert MA, Xu X, Kesari S, Xie XS, Young GS (2012) 'Multicolored stain-free histopathology with coherent Raman imaging'. Laboratory Investigation, 92 (10):1492-1502 [DOI] [Details] | |
| (2012) | 'Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression' Kronenberg G, Balkaya M, Prinz V, Gertz K, Ji S, Kirste I, Heuser I, Kampmann B, Hellmann-Regen J, Gass P, Sohr R, Hellweg R, Waeber C, Juckel G, Hörtnagl H, Stumm R, Endres M (2012) 'Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression'. Biological Psychiatry, 72 (4):273-281 [DOI] [Details] | |
| (2012) | 'Vascular neuroprotection via TrkB- and Akt-dependent cell survival signaling' Guo S, Som AT, Waeber C, Lo EH (2012) 'Vascular neuroprotection via TrkB- and Akt-dependent cell survival signaling'. Journal of Neurochemistry, 123 Suppl 2 :58-64 [DOI] [Details] | |
| (2012) | 'Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke' Campos F, Pérez-Mato M, Agulla J, Blanco M, Barral D, Almeida A, Brea D, Waeber C, Castillo J, Ramos-Cabrer P (2012) 'Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke'. Plos One, 7 (8) [DOI] [Details] | |
| (2011) | 'Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects' Salomone S, Waeber C (2011) 'Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects'. Frontiers In Pharmacology, 2 [DOI] [Details] | |
| (2011) | 'Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice' Eikermann-Haerter K, Yuzawa I, Qin T, Wang Y, Baek K, Kim YR, Hoffmann U, Dilekoz E, Waeber C, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2011) 'Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 31 (15):5755-5763 [DOI] [Details] | |
| (2011) | 'Fingolimod provides long-term protection in rodent models of cerebral ischemia' Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V, Liao JK, Lo EH, Waeber C (2011) 'Fingolimod provides long-term protection in rodent models of cerebral ischemia'. Annals of Neurology, 69 (1):119-129 [DOI] [Details] | |
| (2011) | 'Chronic daily cortical spreading depressions suppress spreading depression susceptibility' Sukhotinsky I, Dilekoz E, Wang Y, Qin T, Eikermann-Haerter K, Waeber C, Ayata C (2011) 'Chronic daily cortical spreading depressions suppress spreading depression susceptibility'. Cephalalgia : an international journal of headache, 31 (16):1601-1608 [DOI] [Details] | |
| (2011) | 'S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells' Hopson KP, Truelove J, Chun J, Wang Y, Waeber C (2011) 'S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells'. The Journal of Physiology, 300 (4):1-26 [DOI] [Details] | |
| (2011) | 'Remote ischemic preconditioning: making the brain more tolerant, safely and inexpensively' Moskowitz MA, Waeber C (2011) 'Remote ischemic preconditioning: making the brain more tolerant, safely and inexpensively'. Circulation, 123 (7):709-711 [DOI] [Details] | |
| (2010) | 'Microemboli may link spreading depression, migraine aura, and patent foramen ovale' Nozari A, Dilekoz E, Sukhotinsky I, Stein T, Eikermann-Haerter K, Liu C, Wang Y, Frosch MP, Waeber C, Ayata C, Moskowitz MA (2010) 'Microemboli may link spreading depression, migraine aura, and patent foramen ovale'. Annals of Neurology, 67 (2):221-229 [DOI] [Details] | |
| (2010) | 'Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries' Salomone S, Soydan G, Ip PC, Hopson KM, Waeber C (2010) 'Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries'. Pharmacological research : the official journal of the Italian Pharmacological Society, 62 (6):465-474 [DOI] [Details] | |
| (2009) | 'Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice' Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC (2009) 'Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice'. Biological Psychiatry, 65 (5):401-408 [DOI] [Details] | |
| (2009) | 'Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1' Eikermann-Haerter K, Dileköz E, Kudo C, Savitz SI, Waeber C, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2009) 'Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1'. The Journal of Clinical Investigation, 119 (1):99-109 [DOI] [Details] | |
| (2008) | 'Stimulus-induced changes in blood flow and 2-deoxyglucose uptake dissociate in ipsilateral somatosensory cortex' Devor A, Hillman EM, Tian P, Waeber C, Teng IC, Ruvinskaya L, Shalinsky MH, Zhu H, Haslinger RH, Narayanan SN, Ulbert I, Dunn AK, Lo EH, Rosen BR, Dale AM, Kleinfeld D, Boas DA (2008) 'Stimulus-induced changes in blood flow and 2-deoxyglucose uptake dissociate in ipsilateral somatosensory cortex'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 28 (53):14347-14357 [DOI] [Details] | |
| (2008) | 'Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection' Kim HH, Sawada N, Soydan G, Lee HS, Zhou Z, Hwang SK, Waeber C, Moskowitz MA, Liao JK (2008) 'Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection'. Blood, 28 (7):1285-1293 [DOI] [Details] | |
| (2008) | 'Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools' Salomone S, Potts EM, Tyndall S, Ip PC, Chun J, Brinkmann V, Waeber C (2008) 'Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools'. British Journal of Pharmacology, 153 (1):140-147 [DOI] [Details] | |
| (2007) | 'Distribution of sphingosine kinase activity and mRNA in rodent brain' Blondeau N, Lai Y, Tyndall S, Popolo M, Topalkara K, Pru JK, Zhang L, Kim H, Liao JK, Ding K, Waeber C (2007) 'Distribution of sphingosine kinase activity and mRNA in rodent brain'. Journal of Neurochemistry, 103 (2):509-517 [DOI] [Details] | |
| (2004) | 'Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats' Reuter U, Salomone S, Ickenstein GW, Waeber C (2004) 'Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats'. Cephalalgia : an international journal of headache, 24 (5):398-407 [DOI] [Details] | |
| (2004) | 'Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells' Harada J, Foley M, Moskowitz MA, Waeber C (2004) 'Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells'. Journal of Neurochemistry, 88 (4):1026-1039 [Details] | |
| (2004) | 'Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors' Waeber C, Blondeau N, Salomone S (2004) 'Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors'. Drug news & perspectives, 17 (6):365-382 [Details] | |
| (2003) | 'Dopamine modulates cell cycle in the lateral ganglionic eminence' Ohtani N, Goto T, Waeber C, Bhide PG (2003) 'Dopamine modulates cell cycle in the lateral ganglionic eminence'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 23 (7):2840-2850 [Details] | |
| (2003) | 'FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice' Yoshimura S, Teramoto T, Whalen MJ, Irizarry MC, Takagi Y, Qiu J, Harada J, Waeber C, Breakefield XO, Moskowitz MA (2003) 'FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice'. The Journal of Clinical Investigation, 112 (8):1202-1210 [DOI] [Details] | |
| (2003) | 'Emerging drugs in migraine treatment' Waeber C (2003) 'Emerging drugs in migraine treatment'. Expert opinion on emerging drugs, 8 (2):437-456 [Details] | |
| (2003) | 'Selective neuronal vulnerability following mild focal brain ischemia in the mouse' Katchanov J, Waeber C, Gertz K, Gietz A, Winter B, Brück W, Dirnagl U, Veh RW, Endres M (2003) 'Selective neuronal vulnerability following mild focal brain ischemia in the mouse'. Brain Pathology, 13 (4):452-464 [Details] | |
| (2003) | 'S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate' Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, Waeber C (2003) 'S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate'. European Journal of Pharmacology, 469 (1-3):125-134 [Details] | |
| (2002) | '5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis' Mitsikostas DD, Sanchez del Rio M, Waeber C (2002) '5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis'. Cephalalgia : an international journal of headache, 22 (5):384-394 [Details] | |
| (2002) | 'Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography' Pejchal T, Foley MA, Kosofsky BE, Waeber C (2002) 'Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography'. British Journal of Pharmacology, 135 (5):1115-1122 [DOI] [Details] | |
| (2001) | 'Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death' Katchanov J, Harms C, Gertz K, Hauck L, Waeber C, Hirt L, Priller J, von Harsdorf R, Bruck W, Hortnagl H, Dirnagl U, Bhide PG, Endres M (2001) 'Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 21 (14):5045-5053 [Details] | |
| (2001) | 'FGF-2 regulation of neurogenesis in adult hippocampus after brain injury' Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, Bakowska JC, Breakefield XO, Moskowitz MA (2001) 'FGF-2 regulation of neurogenesis in adult hippocampus after brain injury'. Proceedings of The National Academy of Sciences of The United States of America, 98 (10):5874-5879 [DOI] [Details] | |
| (2001) | 'Delayed inflammation in rat meninges: implications for migraine pathophysiology' Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R, Theoharides TC, Waeber C, Moskowitz MA (2001) 'Delayed inflammation in rat meninges: implications for migraine pathophysiology'. Brain : a journal of neurology, 124 (Pt 12):2490-2502 [Details] | |
| (2000) | 'Fas receptor and neuronal cell death after spinal cord ischemia' Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L, Hirt L, Waeber C, Hyman BT, Yuan J, Moskowitz MA (2000) 'Fas receptor and neuronal cell death after spinal cord ischemia'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 20 (18):6879-6887 [Details] | |
| (2000) | 'Spinal cord ischemia. Development of a model in the mouse' Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP, Moskowitz MA, Dietrich WD (2000) 'Spinal cord ischemia. Development of a model in the mouse'. Stroke; a journal of cerebral circulation, 31 (1):208-213 [Details] | |
| (2000) | 'Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment' Yamada M, Huang Z, Dalkara T, Endres M, Laufs U, Waeber C, Huang PL, Liao JK, Moskowitz MA (2000) 'Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment'. Blood, 20 (4):709-717 [DOI] [Details] | |
| (1999) | 'Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis' Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C (1999) 'Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis'. European Journal of Pharmacology, 369 (3):271-277 [Details] | |
| (1999) | 'In vitro autoradiographic visualization of guanosine-5'-O-(3-[35S]thio)triphosphate binding stimulated by sphingosine 1-phosphate and lysophosphatidic acid' Waeber C, Chiu ML (1999) 'In vitro autoradiographic visualization of guanosine-5'-O-(3-[35S]thio)triphosphate binding stimulated by sphingosine 1-phosphate and lysophosphatidic acid'. Journal of Neurochemistry, 73 (3):1212-1221 [Details] | |
| (1999) | 'Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor' Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, Geyer MA, Hen R (1999) 'Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor'. Neuron, 22 (3):581-591 [Details] | |
| (1999) | 'Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis' Cutrer FM, Yu XJ, Ayata G, Moskowitz MA, Waeber C (1999) 'Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis'. Pharmacology, 38 (7):1043-1053 [Details] | |
| (1999) | 'Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis' Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA (1999) 'Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis'. British Journal of Pharmacology, 127 (3):623-630 [DOI] [Details] | |
| (1998) | 'Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation' Waeber C, Grailhe R, Yu XJ, Hen R, Moskowitz MA (1998) 'Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation'. Annals of The New York Academy of Sciences, 861 :85-90 [Details] | |
| (1998) | 'Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family' Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gómez-Isla T, Hyman BT, Moskowitz MA (1998) 'Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family'. Blood, 18 (3):238-247 [DOI] [Details] | |
| (1998) | 'Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice' Meng W, Ayata C, Waeber C, Huang PL, Moskowitz MA (1998) 'Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice'. The Journal of Physiology, 274 (2 Pt 2):1-5 [Details] | |
| (1998) | 'The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis' Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM (1998) 'The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis'. Pain, 76 (1-2):239-248 [Details] | |
| (1998) | 'Cerebral dura mater and cephalalgia' Waeber C (1998) 'Cerebral dura mater and cephalalgia'. Cephalalgia : an international journal of headache, 18 (4) [Details] | |
| (1997) | 'Neuropeptides and mast cells' Waeber C (1997) 'Neuropeptides and mast cells'. Cephalalgia : an international journal of headache, 17 (3):143-144 [Details] | |
| (1997) | 'Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase' Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA (1997) 'Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase'. Blood, 17 (11):1143-1151 [DOI] [Details] | |
| (1997) | '[3H]L-NG-nitroarginine binding after transient focal ischemia and NMDA-induced excitotoxicity in type I and type III nitric oxide synthase null mice' Hara H, Ayata C, Huang PL, Waeber C, Ayata G, Fujii M, Moskowitz MA (1997) '[3H]L-NG-nitroarginine binding after transient focal ischemia and NMDA-induced excitotoxicity in type I and type III nitric oxide synthase null mice'. Blood, 17 (5):515-526 [DOI] [Details] | |
| (1997) | 'Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice' Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, Ferrante RJ, Endres M, Kim A, Christie RH, Waeber C, Huang PL, Hyman BT, Moskowitz MA (1997) 'Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice'. The Journal of neuroscience : the official journal of the Society for Neuroscience, 17 (18):6908-6917 [Details] | |
| (1997) | '5-Hydroxytryptamine1A and 5-hydroxytryptamine1B receptors stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography' Waeber C, Moskowitz MA (1997) '5-Hydroxytryptamine1A and 5-hydroxytryptamine1B receptors stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography'. Molecular Pharmacology, 52 (4):623-631 [Details] | |
| (1997) | 'Pulmonary response to inhaled antigen: neuroimmune interactions promote the recruitment of dendritic cells to the lung and the cellular immune response to inhaled antigen' Kradin R, MacLean J, Duckett S, Schneeberger EE, Waeber C, Pinto C (1997) 'Pulmonary response to inhaled antigen: neuroimmune interactions promote the recruitment of dendritic cells to the lung and the cellular immune response to inhaled antigen'. The American journal of pathology, 150 (5):1735-1743 [Details] | |
| (1997) | 'The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater' Yu XJ, Cutrer FM, Moskowitz MA, Waeber C (1997) 'The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater'. Pharmacology, 36 (1):83-91 [Details] | |
| (1996) | 'Brain distribution of nitric oxide synthase in neuronal or endothelial nitric oxide synthase mutant mice using [3H]L-NG-nitro-arginine autoradiography' Hara H, Waeber C, Huang PL, Fujii M, Fishman MC, Moskowitz MA (1996) 'Brain distribution of nitric oxide synthase in neuronal or endothelial nitric oxide synthase mutant mice using [3H]L-NG-nitro-arginine autoradiography'. Science (New York, N.Y.), 75 (3):881-890 [Details] | |
| (1996) | 'Regional distribution and ontogeny of 5-HT4 binding sites in rat brain' Waeber, C; Sebben, M; Bockaert, J; Dumuis, A (1996) 'Regional distribution and ontogeny of 5-HT4 binding sites in rat brain'. Behavioral Brain Research, 73 (1-2) [Details] | |
| (1996) | 'Regional distribution and ontogeny of 5-HT4 binding sites in rat brain' Waeber C, Sebben M, Bockaert J, Dumuis A (1996) 'Regional distribution and ontogeny of 5-HT4 binding sites in rat brain'. Brain : a journal of neurology, 73 (1-2):259-262 [Details] | |
| (1996) | '5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors' Yu XJ, Waeber C, Castanon N, Scearce K, Hen R, Macor JE, Chauveau J, Moskowitz MA (1996) '5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors'. Molecular Pharmacology, 49 (5):761-765 [Details] | |
| (1995) | 'Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor' Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J, Spengler D (1995) 'Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor'. Biochemical Society Transactions, 23 (1):133-137 [Details] | |
| (1995) | 'Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation' Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X, Moskowitz MA (1995) 'Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation'. British Journal of Pharmacology, 116 (1):1661-1667 [Details] | |
| (1995) | '[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study' Waeber C, Moskowitz MA (1995) '[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study'. Naunyn-Schmiedeberg's archives of pharmacology, 352 (3):263-275 [Details] | |
| (1995) | 'Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain' Waeber C, Moskowitz MA (1995) 'Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain'. European Journal of Pharmacology, 283 (1-3):31-46 [Details] | |
| (1995) | 'Induction of nitric oxide synthase activity in rodent brain following middle cerebral artery occlusion' Yoshida T, Waeber C, Huang Z, Moskowitz MA (1995) 'Induction of nitric oxide synthase activity in rodent brain following middle cerebral artery occlusion'. Neuroscience Letters, 194 (3):214-218 [Details] | |
| (1994) | '5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes' Schoeffter P, Waeber C (1994) '5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes'. Naunyn-Schmiedeberg's archives of pharmacology, 350 (4):356-360 [Details] | |
| (1994) | 'Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia' Waeber C, Palacios JM (1994) 'Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia'. Brain : a journal of neurology, 24 (1-4):199-209 [Details] | |
| (1994) | 'Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain' Waeber C, Sebben M, Nieoullon A, Bockaert J, Dumuis A (1994) 'Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain'. Neuropharmacology, 33 (3-4):527-541 [Details] | |
| (1993) | '[3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain' Waeber C, Sebben M, Grossman C, Javoy-Agid F, Bockaert J, Dumuis A (1993) '[3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain'. Neuroreport, 4 (11):1239-1242 [Details] | |
| (1993) | 'Differential signal transduction by five splice variants of the PACAP receptor' Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L (1993) 'Differential signal transduction by five splice variants of the PACAP receptor'. Nature, 365 (6442):170-175 [DOI] [Details] | |
| (1992) | 'Activation of 5-HT1A receptors expressed in NIH-3T3 cells induces focus formation and potentiates EGF effect on DNA synthesis' Varrault A, Bockaert J, Waeber C (1992) 'Activation of 5-HT1A receptors expressed in NIH-3T3 cells induces focus formation and potentiates EGF effect on DNA synthesis'. Biology of The Cell / Under The Auspices of The European Cell Biology Organization, 3 (9):961-969 [Details] | |
| (1992) | 'Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes' Pin JP, Waeber C, Prezeau L, Bockaert J, Heinemann SF (1992) 'Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes'. Proceedings of The National Academy of Sciences of The United States of America, 89 (21):10331-10335 [Details] | |
| (1992) | 'Direct visualization of serotonin1D receptors in the human brain using a new iodinated radioligand' Palacios JM, Waeber C, Bruinvels AT, Hoyer D (1992) 'Direct visualization of serotonin1D receptors in the human brain using a new iodinated radioligand'. Brain : a journal of neurology, 13 (1-2):175-178 [Details] | |
| (1992) | '5-HT1R or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain' Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM (1992) '5-HT1R or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain'. Naunyn-Schmiedeberg's archives of pharmacology, 346 (3):249-254 [Details] | |
| (1992) | 'Non 5-HT1A/5-HT1C [3H]5-HT binding sites in the hamster, opossum, and rabbit brain show similar regional distribution but different sensitivity to beta-adrenoceptor antagonists' Waeber C, Palacios JM (1992) 'Non 5-HT1A/5-HT1C [3H]5-HT binding sites in the hamster, opossum, and rabbit brain show similar regional distribution but different sensitivity to beta-adrenoceptor antagonists'. Synapse (New York, N.Y.), 12 (4):261-270 [DOI] [Details] | |
| (1991) | 'Autoradiography of 5-HT receptors: A critical appraisal' Palacios J, Waeber C, Mengod G, Hoyer D (1991) 'Autoradiography of 5-HT receptors: A critical appraisal'. Neurochemistry International, 18 (1):17-25 [Details] | |
| (1991) | 'Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease' Waeber C, Rigo M, Chinaglia G, Probst A, Palacios JM (1991) 'Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease'. Synapse (New York, N.Y.), 8 (4):270-280 [DOI] [Details] | |
| (1991) | 'Neurophysins, rather than Receptors, are Involved in [H]Oxytocin and [H]Vasopressin Binding Detected by Autoradiography in the Hypothalamo-Neurohypophyseal System' Freund-Mercier MJ, Stoeckel ME, Waeber C, Kremarik P, Palacios JM, Richard P (1991) 'Neurophysins, rather than Receptors, are Involved in [H]Oxytocin and [H]Vasopressin Binding Detected by Autoradiography in the Hypothalamo-Neurohypophyseal System'. Journal of Neuroendocrinology, 3 (3):285-295 [DOI] [Details] | |
| (1991) | 'Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand' Bruinvels AT, Landwehrmeyer B, Waeber C, Palacios JM, Hoyer D (1991) 'Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand'. European Journal of Pharmacology, 202 (1):89-91 [Details] | |
| (1990) | 'Serotonin 5-HT1D receptors' Hoyer D, Schoeffter P, Waeber C, Palacios JM (1990) 'Serotonin 5-HT1D receptors'. Annals of The New York Academy of Sciences, 600 :168-11 [Details] | |
| (1990) | 'The serotonin 5-HT1D receptor: a progress review' Waeber C, Schoeffter P, Hoyer D, Palacios JM (1990) 'The serotonin 5-HT1D receptor: a progress review'. Neurochemical research, 15 (6):567-582 [Details] | |
| (1990) | 'Distribution of serotonin receptors' Palacios JM, Waeber C, Hoyer D, Mengod G (1990) 'Distribution of serotonin receptors'. Annals of The New York Academy of Sciences, 600 :36-52 [Details] | |
| (1990) | 'The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution' Mengod G, Nguyen H, Le H, Waeber C, Lübbert H, Palacios JM (1990) 'The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution'. Science (New York, N.Y.), 35 (3):577-591 [Details] | |
| (1990) | '5-HT1 receptor binding sites in the guinea pig superior colliculus are predominantly of the 5-HT1D class and are presynaptically located on primary retinal afferents' Waeber C, Palacios JM (1990) '5-HT1 receptor binding sites in the guinea pig superior colliculus are predominantly of the 5-HT1D class and are presynaptically located on primary retinal afferents'. Brain : a journal of neurology, 528 (2):207-211 [Details] | |
| (1990) | '5-HT1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway' Waeber C, Zhang LA, Palacios JM (1990) '5-HT1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway'. Brain : a journal of neurology, 528 (2):197-206 [Details] | |
| (1990) | 'The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain' Waeber C, Pinkus LM, Palacios JM (1990) 'The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain'. European Journal of Pharmacology, 181 (3):283-287 [Details] | |
| (1990) | 'Similar distribution of [125I]sarafotoxin-6b and [125I]endothelin-1, -2, -3 binding sites in the human kidney' Waeber C, Hoyer D, Palacios JM (1990) 'Similar distribution of [125I]sarafotoxin-6b and [125I]endothelin-1, -2, -3 binding sites in the human kidney'. European Journal of Pharmacology, 176 (2):233-236 [Details] | |
| (1989) | '5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization' Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A (1989) '5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization'. Naunyn-Schmiedeberg's archives of pharmacology, 339 (3):252-258 [Details] | |
| (1989) | '[125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans' Hoyer D, Waeber C, Palacios JM (1989) '[125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans'. Journal of Cardiovascular Pharmacology, 13 Suppl 5 :1-5 [Details] | |
| (1989) | 'Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study' Waeber C, Palacios JM (1989) 'Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study'. Science (New York, N.Y.), 32 (2):337-347 [Details] | |
| (1989) | 'GR 43175: a preferential 5-HT1D agent in monkey and human 1rains as shown by autoradiography' Waeber C, Hoyer D, Palacios JM (1989) 'GR 43175: a preferential 5-HT1D agent in monkey and human 1rains as shown by autoradiography'. Synapse (New York, N.Y.), 4 (2):168-170 [DOI] [Details] | |
| (1989) | '5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930' Waeber C, Hoyer D, Palacios JM (1989) '5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930'. Neuroscience, 31 (2):393-400 [Details] | |
| (1989) | '[3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion' Hoyer D, Waeber C, Karpf A, Neijt H, Palacios JM (1989) '[3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion'. Naunyn-Schmiedeberg's archives of pharmacology, 340 (4):396-402 [Details] | |
| (1989) | '5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography' Waeber C, Dietl MM, Hoyer D, Palacios JM (1989) '5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography'. Naunyn-Schmiedeberg's archives of pharmacology, 340 (5):486-494 [Details] | |
| (1989) | '5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies' Waeber C, Schoeffter P, Palacios JM, Hoyer D (1989) '5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies'. Naunyn-Schmiedeberg's archives of pharmacology, 340 (5):479-485 [Details] | |
| (1988) | 'Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography' Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM (1988) 'Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography'. Neuroscience Letters, 88 (1):11-16 [Details] | |
| (1988) | 'The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra' Schoeffter P, Waeber C, Palacios JM, Hoyer D (1988) 'The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra'. Naunyn-Schmiedeberg's archives of pharmacology, 337 (6):602-608 [Details] | |
| (1988) | 'Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes' Waeber C, Schoeffter P, Palacios JM, Hoyer D (1988) 'Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes'. Naunyn-Schmiedeberg's archives of pharmacology, 337 (6):595-601 [Details] | |
| (1988) | 'Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites' Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM (1988) 'Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites'. Neuroscience Letters, 85 (3):357-362 [Details] | |
| (1988) | 'Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS' Waeber C, Dixon K, Hoyer D, Palacios JM (1988) 'Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS'. European Journal of Pharmacology, 151 (2):351-352 [Details] |
Book Chapters
| Year | Publication | |
|---|---|---|
| (2016) | 'Cerebral blood flow methods' Waeber, C (2016) 'Cerebral blood flow methods' In: Louis R. Caplan, Jose Biller, Megan Leary, Ajith Thomas, Eng Lo, Midori Yenari, and John Zhang (eds). Primer on Cerebrovascular Diseases, Second Edition. Philadelphia: Elsevier. [Details] | |
| (1989) | 'Visualization of serotonin receptor binding and their messenger RNAs in the mammalian brain: an update' Palacios, JM; Waeber, C; Mengod, G; Hoyer, D (1989) 'Visualization of serotonin receptor binding and their messenger RNAs in the mammalian brain: an update' In: Serotonin: From Cell Biology to Pharmacology and Therapeutics. Dordrecht: Kluwer Academic Publishers. [Details] | |
| (1991) | '5-HT1C, 5-HT1D and 5-HT2 receptors in mammalian brain: multiple affinity states with a different regional distribution' Waeber, C; Palacios, JM (1991) '5-HT1C, 5-HT1D and 5-HT2 receptors in mammalian brain: multiple affinity states with a different regional distribution' In: Serotonin: Molecular Biology, Receptors and Functional Effects. Basel: Birkhauser. [Details] | |
| (1991) | 'Molecular neuroanatomy of 5-HT receptors' Palacios, JM; Waeber, C; Mengod, G; Pompeiano, M (1991) 'Molecular neuroanatomy of 5-HT receptors' In: Serotonin: Molecular Biology, Receptors and Functional Effects. Basel: Birkhauser. [Details] | |
| (1994) | 'The 5-HT1D receptor subtype and migraine headache' Moskowitz, MA; Waeber, C (1994) 'The 5-HT1D receptor subtype and migraine headache' In: Cell Signal Transduction, Second Messengers, and Protein Phosphorylation in Health and Disease. New York: Springer. [Details] | |
| (2008) | 'Future targets for headache therapy: Prostanoids' Waeber, C (2008) 'Future targets for headache therapy: Prostanoids' In: Frontiers in Headache Research 16: Innovative drug development for headache disorders. New York: Oxford University Press. [Details] | |
| (1991) | 'Multiple serotonin receptors in the human brain' Pazos, A; Waeber, C; Gonzalez, A; Palacios, J (1991) 'Multiple serotonin receptors in the human brain' In: The Human nervous system. Vol. 3: Receptors in the human nervous system. San Diego: Academic Press. [Details] | |
| (1993) | 'Autoradiography of 5-HT receptors' Waeber, C; Palacios, J (1993) 'Autoradiography of 5-HT receptors' In: Receptor Autoradiography: Principles and Practice. Oxford: Oxford University Press. [Details] | |
| (1995) | 'Drug discovery in migraine circa 1995' Moskowitz, MA; Cutrer, FM; Lee, WS; Waeber, C; Limmroth, V; Yu, X (1995) 'Drug discovery in migraine circa 1995' In: Experimental Headache Models in Animal and Man. New York: Raven Press. [Details] | |
| (1997) | 'New targets for antimigraine drug development' Cutrer, FM; Limmroth, V; Waeber, C; Yu, XJ; Moskowitz MA (1997) 'New targets for antimigraine drug development' In: Headache. Oxford: Butterworth-Heinnemann. [Details] | |
| (1997) | 'Neuronal pathophysiology of migraine as a basis for acute treatment with 5-HT receptor ligands' Moskowitz, MA; Waeber, C (1997) 'Neuronal pathophysiology of migraine as a basis for acute treatment with 5-HT receptor ligands' In: Handbook of Experimental Pharmacology, Vol 128, Serotoninergic neurons and 5-HT receptors in the CNS. Berlin: Springer Verlag. [Details] | |
| (1997) | '5-HT4 receptors. IN Serotonin receptors and their ligands' Dumuis, A; Ansanay, H; Waeber, C; Sebben, M; Fagni, L; Bockaert, J (1997) '5-HT4 receptors. IN Serotonin receptors and their ligands' In: Serotonin receptors and their ligands. Amsterdam: Elsevier. [Details] | |
| (1998) | 'Diagnosis and management of headache' Cutrer, FM; Waeber, C; Moskowitz, MA (1998) 'Diagnosis and management of headache' In: Pharmacological management of neurological and psychiatric disorders. New York: McGraw-Hill. [Details] | |
| (2002) | 'Headaches' Cutrer, FM; Waeber, C; Moskowitz, MA (2002) 'Headaches' In: Baker’s Clinical Neurology. Philadelphia: Lippincott Williams and Wilkins. [Details] | |
| (2005) | 'Prostanoids and Other Inflammatory Mediators' Waeber, C (2005) 'Prostanoids and Other Inflammatory Mediators' In: The Headaches. Philadelphia: Lippincott, Williams and Wilkins. [Details] | |
| (2005) | 'Serotonin and Other Biogenic Amines' Waeber, C (2005) 'Serotonin and Other Biogenic Amines' In: The Headaches. Philadelphia: Lippincott, Williams and Wilkins. [Details] | |
| (2010) | 'Current and emerging therapies for migraine prevention and treatment' Waeber C, Hargreaves R (2010) 'Current and emerging therapies for migraine prevention and treatment' In: Handbook of Clinical Neurology, Vol. 97 (3rd series). Amsterdam: Elsevier. [DOI] [Details] | |
| (2013) | 'Sphingosine –phosphate (S1P) signaling and the vasculature' Waeber, C (2013) 'Sphingosine –phosphate (S1P) signaling and the vasculature' In: Lysophospholipid Receptors: Signaling and Biochemistry. Hoboken, NJ: John Wiley & Sons, Inc. [DOI] [Details] |
Other Journals
| Year | Publication | |
|---|---|---|
| (1990) | 'Distribution of serotonin receptors' Palacios, JM; Waeber, C; Hoyer, D; Mengod, G (1990) 'Distribution of serotonin receptors' Ann NY Acad Sci, 600 :36-52. [Details] | |
| (1990) | 'Serotonin 5HT1D receptors' Hoyer, D; Schoeffter, P; Waeber, C; Palacios, JM (1990) 'Serotonin 5HT1D receptors' Ann NY Acad Sci, 600 :168-182. [Details] | |
| (1998) | 'Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation' Waeber, C; Grailhe, R; Yu, XJ; Hen, R; Moskowitz, MA (1998) 'Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation' Ann NY Acad Sci, 861 :85-90. [DOI] [Details] | |
| (1992) | 'Autoradiographic localization of 5-HT receptor subtypes' Palacios, J; Mengod, G; Hoyer, D; Waeber, C; Pompeiano, M; Niclou, S; Bruinvels, A (1992) 'Autoradiographic localization of 5-HT receptor subtypes' Adv Biosci, 85 :61-72. [Details] | |
| (1994) | '5-HT4 receptors: potential therapeutic implications in neurology and psychiatry' Bockaert, J; Ansanay, H; Waeber, C; Sebben, M; Fagni, L; Dumuis, A (1994) '5-HT4 receptors: potential therapeutic implications in neurology and psychiatry' CNS Drugs, 1 :6-15. [Details] | |
| (1995) | 'Sumatriptan: aktuelle Erkenntnisse zu Pharmakologie, Wirkungsmechanismus und klinischem Einsatz' Limmroth, V; Waeber, C; Diener, HC (1995) 'Sumatriptan: aktuelle Erkenntnisse zu Pharmakologie, Wirkungsmechanismus und klinischem Einsatz' Aktuelle Neurologie, 22 :31-39. [Details] | |
| (1995) | 'Migraine enters the molecular era' Moskowitz, MA; Waeber, C (1995) 'Migraine enters the molecular era' The Neuroscientist, 2 :191-200. [Details] | |
| (1997) | 'Neuropeptides and mast cells' Waeber, C (1997) 'Neuropeptides and mast cells' Cephalalgia, 17 :143-144. [Details] | |
| (1998) | 'The role of 5-HT1B/1D receptors in the treatment of migraine' Waeber, C (1998) 'The role of 5-HT1B/1D receptors in the treatment of migraine' CNS Spectrums, 3 :30-39. [Details] | |
| (1998) | 'Cerebral dura mater and cephalalgia' Waeber, C (1998) 'Cerebral dura mater and cephalalgia' Cephalalgia, 18 (4) . [Details] | |
| (2001) | 'Emerging Concepts in migraine pathophysiology' Moskowitz, MA; Reuter, U; Waeber, C (2001) 'Emerging Concepts in migraine pathophysiology' Confinia Cephalalgica, 10 :171-176. [Details] | |
| (2003) | 'Emerging drugs in migraine treatment' Waeber, C (2003) 'Emerging drugs in migraine treatment' Expert Opin Emerg Drugs, 8 (2) :437-456. [Details] | |
| (2003) | 'Therapeutic implications of central and peripheral neurologic mechanisms in migraine' Waeber, C; Moskowitz, MA (2003) 'Therapeutic implications of central and peripheral neurologic mechanisms in migraine' Neurology, 61 :S9-S20. [Details] | |
| (2004) | 'Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors' Waeber C; Blondeau N; Salomone S (2004) 'Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors' Drug News Perspect, 17 (6) :365-382. [Details] | |
| (2005) | 'Migraine as an inflammatory disorder' Waeber, C; Moskowitz, MA (2005) 'Migraine as an inflammatory disorder' Neurology, 64 (10 Suppl 2) :S9-S15. [Details] | |
| (2007) | 'Targeting neuronal hyperexcitability for antimigraine drug development' Waeber, C (2007) 'Targeting neuronal hyperexcitability for antimigraine drug development' Future Neurology, 2 :179-188. [DOI] [Details] |
Professional Activities
Honours and Awards
| Year | Title | Awarding Body | |
|---|---|---|---|
| 1990 | Vigener Prize | University of Fribourg, Switzerland | |
| 1990 | Serotonin Club Special Award | Serotonin Club |
Employment
| Employer | Position | From / To | |
|---|---|---|---|
| Harvard Medical School | Assistant professor of surgery | 01-JAN-98 / 31-JAN-07 | |
| Harvard Medical School | Assistant professor of radiology | 01-FEB-07 / 31-DEC-09 | |
| Novartis Basel (Switzerland) | Ph.D. Student | 01-JAN-87 / 28-FEB-91 | |
| INSERM, Montpellier (France) | Post-doctoral fellow ("Poste vert") | 01-MAR-91 / 28-FEB-93 | |
| Partners Healthcare (Boston, MA) | Principal Investigator, associate biochemist | 19-SEP-93 / 31-DEC-12 | |
| Harvard Medical School | Associate Professor of Radiology | 01-JAN-10 / 31-DEC-12 | |
| University College Cork | Senior Lecturer in Pharmacology | 01-JAN-13 / |
Languages
| Language | Reading | Writing | Speaking | |
|---|---|---|---|---|
| Spanish | Functional | Basic | Basic | |
| German | Fluent | Functional | Functional | |
| Italian | Fluent | Functional | Functional | |
| English | Fluent | Fluent | Fluent | |
| French | Fluent | Fluent | Fluent |
Journal Activities
| Journal | Role | To / From | |
|---|---|---|---|
| Journal Of Cellular Biochemistry | Referee | - | |
| Nature Reviews Neuroscience | Referee | - | |
| Stroke | Referee | - | |
| European Journal Of Neuroscience | Referee | - | |
| Journal Of The Neurological Sciences | Referee | - | |
| Journal Of Neurotrauma | Referee | - | |
| Neuroscience Letters | Referee | - | |
| Progress In Neurobiology | Referee | - | |
| Autonomic & Autacoid Pharmacology | Referee | - | |
| Synapse (New York, N.Y.) | Referee | - | |
| British Journal Of Pharmacology | Referee | - | |
| Journal Of Neuroscience | Referee | - | |
| Molecular Pharmacology | Referee | - | |
| Life Sciences | Referee | - | |
| Cephalalgia : An International Journal Of Headache | Referee | - | |
| Brain Research | Referee | - | |
| European Journal Of Pharmacology | Referee | - | |
| Neuropharmacology | Referee | - | |
| Naunyn-Schmiedeberg'S Archives Of Pharmacology | Referee | - | |
| Frontiers In Pharmacology | Editor | - |
Teaching Activities
Teaching Interests
Pathophysiology and pharmacology of migraine and stroke.Biochemical pharmacology of G protein-coupled receptors
Vascular physiology
Central Nervous System Pharmacology and Therapeutics
Contact details
- Christian Waeber
- c.waeber@ucc.ie
- +353-21-490-3000
- Professor of Pharmacology
- c.waeber@ucc.ie
- Pharmacy Building
College Road
Cork - +353 21 490 1791